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2
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Abstract: The study reported describes a combination of recombinant human bone
morphogenetic protein-2 (rhBMP-2) and collagen (C) to regenerate bone. Unilateral
critical-sized defects (CSDs) were prepared in radii of 32 skeletally mature New Zealand
white rabbits. Rabbits were divided evenly among four treatments: autograft, absorbable
C (Helistat威), 35 mg of rhBMP-2 combined with absorbable C (rhBMP-2/C), and untreated CSDs. The two euthanasia periods were 4 and 8 weeks. Radiographs were taken
the day of surgery, every 2 weeks, and at term and the percent of radiopacity was
measured. Data analysis revealed a time-dependent increase in the percent radiopacity
with rhBMP-2/C. Histological examination revealed the rhBMP-2/C treatment regenerated osseous contour by 8 weeks. According to quantitative histomorphometry, the CSD
and C groups had significantly less new bone than either autograft or rhBMP-2/C (p °
0.05). The results suggest that rhBMP-2/C could be an effective therapy to restore segmental bone defects.
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INTRODUCTION

The capacity for bone to regenerate is well known. However, the ability to restore form and function without scar
formation is size limited and the concept of the criticalsized defect (CSD) reflects this physiologic phenomenon. 1
Augmentation of bone deficits with various therapies has
become a common practice, and autogenous grafts and
allogeneic bone bank preparations provide effective therapies. Yet, despite the effectiveness of these traditional therapies, recognized liabilities 2,3 have prompted a quest for
alternatives.4 A potential alternative has been developed
that consists of recombinant human bone morphogenetic
protein-2 (rhBMP-2) and collagen (C).
The efficacy and safety of rhBMPs were well documented in numerous preclinical trials in several animal
models 5 – 13 and in a recent provocative clinical report. 14 A
reoccurring theme in these studies was the emphasis on
the delivery system for rhBMP. The delivery system fulfills
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important roles, such as allowing the surgical placement
of the therapeutic agent, preventing soft tissue prolapse,
and localizing rhBMP-2 at the wound site for interaction
with cells. Several categories of materials were selected as
delivery systems for BMPs, including calcium-phosphates,
biodegradable polymers, bone derivatives, and C. 15 Selection criteria for delivery systems were based on expediency
and physiological merit: expediency because some materials were available as clinical therapies acceptable to the
Food and Drug Administration (FDA) and physiological
merit because some materials fulfill biological, functional
roles. We selected a C vehicle for rhBMP-2 based on the
notion that a commercially available, FDA-approved C
therapy for hemostasis could deliver rhBMP-2 and promote
bone regeneration. This notion is not unfounded because
demineralized bone matrix, principally type I collagen and
soluble signaling factors (including BMPs), has a proven
record for bone repair. 16
In light of the bone inductive potency of rhBMP-2 and
the conviction that a commercially available C therapeutic
would fulfill an effective role as a delivery system, we
proposed the hypothesis that the combination of a selected
dose of rhBMP-2 plus Helistat威 C (rhBMP-2/C) would
promote an amount of bone equivalent to a traditional
‘‘gold standard’’ (i.e., autograft). Therefore, to test this
hypothesis we designed a study using a CSD segmental

Surgical Procedures and Treatment

Figure 1. A scanning electron microscope micrograph reveals the
highly fibrous and porous structure of the collagen delivery system.

wound model and four treatment groups: autograft, rhBMP2/C, C, or untreated CSD.
Our goal is to develop a therapy that may be an alternative to either autografts or allogeneic preparations. Based
on the evidence from this study, it appears rhBMP-2/C
may be an effective therapy to restore segmental osseous
defects.

MATERIALS AND METHODS

Unilateral, 20-mm length CSD ostectomies were prepared
in the radial diaphyses of 32 skeletally mature New Zealand
rabbits. Skeletal maturity was verified radiographically by
closure of the epiphyseal plates. The 32 rabbits were divided evenly between two time periods (4 and 8 weeks)
and among four treatment groups. Treatments consisted of
autograft, untreated ostectomy, and Helistat威 C either alone
or with 35 mg of rhBMP-2.
The rhBMP-2 was produced by a Chinese hamster ovarian cell expression system. The protein was purified to
ú98%, placed in sterile glass vials containing a sodium
glutamate buffer (5 mM, pH 4.5), and closed with rubber
stoppers. The rhBMP-2 was provided by Genetics Institute
(Andover, MA). Helistat威 C (Fig. 1) was prepared in a
proprietary manner by Colla-Tech, Inc. (a subsidiary of
Integra Life Sciences Corporation, Plainsboro, NJ) from
bovine tendon. Helistat威 is a crosslinked atelopeptide product that is nonimmunogenic and composed of type I collagen. The ability of Helistat威 plus rhBMP-2 to promote
bone formation was confirmed by previous studies. 17,18
/
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Surgery. The New Zealand white rabbits were anesthetized with 10 mL of ketamine hydrochloride, 100 mg/mL
Ketaset (Fort Dodge Laboratories, Inc., Fort Dodge, IA),
5 mL of xylazine, and 20 mg/mL Gemini SA (Burns Veterinary Supply, Inc., Rockville Center, NY) at a dose of 0.65
mL/kg body weight administered intramuscularly (i.m.).
Enrofloxacin (25 mg/kg, Baytril, Miles Inc., Shawnee Mission, KS) was given i.m. The operative site on either the
left or right front limb was shaved, prepped, and draped
for aseptic surgery with the rabbit in the supine position.
A tourniquet was placed around the axillary region and the
operative site was infiltrated with 0.5 mL of 2% lidocaine
with epinephrine 1:100,000, 20 mg/mL xylocaine (Astra
Pharmaceutical Products Inc., Westborough, MA). A 4cm length superomedial incision was made and the tissues
were dissected overlying the diaphysis of the radius. A 20mm segmental defect was made in the radius with a surgical
oscillating saw supplemented by copious 0.9% sterile saline irrigation, and the appropriately designated treatment
was placed in the CSD. Fixation of the ostectomized bone
was unnecessary due to the fibro-osseous union between
the ulna and radius located distal and proximal to the surgical site. The soft tissues were approximated with interrupted 4-0 Vicryl sutures (Ethicon Inc., Somerville, NJ)
and the skin was closed with surgical staples (Precise DS25, 3M, St. Paul, MN). Immediately after surgery, standardized lateral radiographs were taken of the operated
limb after which the animals were returned to their individual cages. Postoperative analgesia (Buprenex, 0.3 mg/mL,
0.3 mL i.m., Reckitt and Coleman Pharmaceuticals Inc.,
Richmond, VA) was given as needed. Water and food were
supplied ad libidum.
Treatments. The autograft was prepared as a corticocancellous block from the operated site. For the C and
rhBMP-2/C treatments, 0.17 mL of buffer containing either 0 or 35 mg of rhBMP-2 was transferred in a sterile
fashion to the collagen by syringe and placed within the
ostectomy gap [Fig. 2(A,B)]. Treatments were retained
and stabilized by approximating flexor and extensor tendons and simple soft tissue closure. The fourth group consisted of untreated CSDs.
There were four rabbits for each experimental cohort at
each time period. This quantity was determined by power
analysis from previous data, 19,20 indicating that the a risk
would be 0.05 and the b risk would be 0.10. 21

Radiography and Radiomorphometry

Standardized radiographs were taken immediately postoperatively, every 2 weeks in life, and at the time of euthanasia. Briefly, the surgical sites were radiographed in a standard manner in a Minishot X-ray cabinet (AXR Corporation, East Haven, CT) at 35 kvp, 3 mA, and 25 s using a
constant object to film to X-ray cone distance and ultrahigh
jbma
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(Zeiss Instruments Co., Inc., New York). New bone was
detected and measured in square millimeters from the von
Kossa stained specimens using a Leica 970 Image Analysis
System (Leica Instruments Ltd., Cambridge, U.K.) interfaced with a Zeiss Axiophot microscope as previously described. 20,22

Statistical Analyses

Histomorphometry and radiomorphometry data were analyzed by multiple ANOVA to determine if there was an
overall difference in the percent of radiopacity and area of
new bone among treatments over time. Individual differences between treatments at each time period were determined by Fisher’s protected least significant difference test
for multiple comparisons. Statistical significance was established at p õ 0.05.

RESULTS

The clinical course for all treatments was uneventful. There
were no indications of adverse sequelae.

Radiography

Figure 2. (A) At the time of surgery, 0.17 mL of buffer containing
either 0 or 35 mg of rhBMP-2 was transferred in a sterile fashion by
syringe to the collagen delivery vehicle. (B) The rhBMP-2/C within
the ostectomy gap. (䉱) The edges of the resected radius.

contrast mammography film (X-OMATL, Kodak, Eastman
Kodak, Rochester, NY). The X-ray films were assessed by
gray level densities and were reported as ‘‘percent radiopacity’’ across the ostectomy as previously described. 20,22
A standard-sized computer-generated reference frame was
used for each experimental site; if radiopacity completely
filled the site, a value of 100% radiopacity was recorded.

Throughout the 8-week study, the CSDs did not achieve a
radiopaque union. Autograft-treated recipient sites displayed callus formation at 4 and 8 weeks, and consolidation
was more evident at 8 weeks than at 4 weeks. Minimal
radiopacity was observed at the bone margins for the C
cohort at 4 and 8 weeks; by 8 weeks the recipient sites
treated with rhBMP-2/C had radiopaque bridging (Fig. 3).
Figure 4 depicts the radiographic progression for the
CSD and 35 mg rhBMP-2/C treatments immediately following surgery and until necropsy. Radiolucency immediately following surgery (postop day 0) is evident in the
35-mg rhBMP-2/C group, and from 2 through 4 weeks the
radiopacity gradually increased. At 6 weeks a bonelike
pattern could be noted, and by 8 weeks radiopaque bridging
with a contour reminiscent of the preostectomized segment
was apparent. (Verification that radiopacity is new bone
was made by histology.)

Histology and Histomorphometry

Following euthanasia, experimental sites were recovered
as a block and placed immediately into 70% ethanol, taken
to 100% ethanol, embedded in poly(methylmethacrylate),
sectioned to a 5-mm thickness, and consecutive serial sections stained either with a modification of the Goldner–
Masson trichrome stain or von Kossa stain. Using bright
field light microscopy, the Goldner–Masson trichromestained sections were examined for cell type, morphology,
and stromal detail using a Zeiss Axiophot Microscope
/
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Radiomorphometry

The 35-mg rhBMP-2/C treatment promoted a significant
increase in the percent of radiopacity from 2 to 4 weeks,
after which time there was no difference (Fig. 5). Furthermore, 35-mg rhBMP-2/C treated sites displayed significantly more radiopacity than either the CSD or C-treated
defects throughout the experiment’s duration. In contrast,
the autograft recipient beds had a relatively consistent pattern of radiopacity.
jbma
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Figure 3. Representative radiographs of the four treatments at 8 weeks. The radiolucent CSD validates that the 20-mm ostectomy does not heal by bone formation. A radiolucent junction may be
seen between the autograft and host bone (䉮). The 0 mg of rhBMP-2 delivered in C is radiolucent.
The 35 mg of rhBMP-2 and collagen treatment promoted new cortical bone . The host bone is
identified by (䉱).

Histology and Histomorphometry

A series of light micrographs for each treatment at 4 and
8 weeks depicts the appearance wound beds (Fig. 6). At
4 weeks the recipient beds administered 35 mg rhBMP2/C had numerous bony trabeculae. By 8 weeks the trabeculae were consolidating and cortices were reforming. In
contrast, experimental sites treated with either C or left as
untreated CSDs gradually went on to a fibrotic union. The
autografts integrated with the host bone through callus formation.
Residual C was detected microscopically with polarized
light at 4 weeks; none could be detected by 8 weeks (Fig.
7). Moreover, there was no evidence of an adverse cellular
reaction to the C at either 4 or 8 weeks.
Histomorphometric data indicated the CSD and C
groups had significantly less bone than the other two
groups, whereas no difference was detected between the
35-mg rhBMP-2/C and autograft groups (Fig. 8).

DISCUSSION

The results comply with our purpose to regenerate CSDs
in rabbits’ radii with rhBMP-2 and C. Furthermore, we
proved the stated hypothesis that a combination of rhBMP2 and C would regenerate as much bone as the gold standard autograft. The autograft formulation has been applied
in previous rabbit studies in our laboratory. Moreover, the
bone formation response evoked by the segmental autograft
could be measured and compared to the bone formation
response promoted by the other experimental treatments.
We selected a dose of 35 mg of rhBMP-2 combined with
C for comparison to the autograft. This decision was based
on previous investigations using the same wound model in
rabbits. 19,20 Reports on long bone regeneration with either
/
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partially purified BMP or rhBMP and various delivery systems used a range of doses, different animal models, and
assorted time periods for assessments. Therefore, it was
problematic to extrapolate BMP doses from these studies.
However, some key features from these investigations provided valuable guidance and should be emphasized to underscore crucial issues of reproducibility and accuracy in
animal wound modeling, experimental design, BMP dosing, and BMP delivery that impact on a therapy for patients.
Stevenson and colleagues prepared bilateral diaphyseal
defects (8 mm in length) in rat femora and reconstructed
them with combinations of hydroxyapatite and tricalcium
phosphate (HA/TCP) amended with 100 mg of partially
purified bovine osteogenin (also known as BMP-3). 23 This
dose combined with the HA/TCP cylinder promoted more
bone formation in the HA/TCP devices than HA/TCP
without osteogenin. However, Stevenson et al. determined
there was no biomechanical difference between the two
treatment cohorts (i.e., HA/TCP vs. 100 mg BMP-3/HA/
TCP). 23 Another long bone study in rat femora involved
unilateral defects that were 4 mm in length. 24 The authors
reported that at 4 and 8 weeks only the 10 mg of extract
from Saos-2 cells with bovine collagen promoted bone
union. 24
Yasko et al. used a combination of rhBMP-2 (either 1.4
or 11 mg) and guanidine-hydrochloride extracted demineralized rat bone matrix to regenerate ostectomies in rat femora. 25 Their evidence suggested that the 11-mg rhBMP-2
dose caused radiographic bridging of the 5-mm ostectomy
gaps. The authors reported that by week 9 there was a
cortical bridge across the defect with reconstitution of the
intramedullary canal.
Marden and coworkers administered either 2.2 or 6.5
mg of rhBMP-2 with guanidine-hydrochloride extracted demineralized rat bone matrix in craniotomies in rats and
jbma
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Figure 4. The radiographic progression CSDs and 35 mg of rhBMP-2 and collagen treatment from
the day of surgery until euthanasia (8 weeks). Both treatments at postop day 0 are radiolucent
immediately after ostectomy. The 35 mg of rhBMP-2 and collagen became slightly radiopaque by 2
weeks. Radiopacity for this treatment increased from 4 through 8 weeks, at which time a dense
radiopaque bridging with a contour reminiscent of the preostectomized segment was apparent.

determined that by 14 days, 6.5 mg of rhBMP-2 completely
regenerated the craniotomy. 7 In contrast, with a dose of 11
mg rhBMP-2 Yasko and associates observed radiographic
bridging by 4.5 weeks and restoration of the cortex and
medullary canal by 9 weeks. 25 These two rat studies are
highlighted to underscore the variability in doses between
two experiments exploiting the same animal and delivery
system for rhBMP-2 at different recipient sites. Therefore,
it is noteworthy to review several key observations. In rats,
irrespective of embryogenesis, the intramembranous skull
CSD and the endochondral femur CSD will regenerate in
response to rhBMP-2. The rate of bone healing appears to
be site specific; for example, the skull CSD regenerated in
2 weeks (with 6.5 mg rhBMP-2) whereas the femur (with
11 mg rhBMP-2) required 9 weeks. This observation may
be due to enriched vascularity and cellularity of the cranio/
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facial complex versus an extremity. Moreover, recombinant
BMP appears to be 10 000 times more potent than partially
purified BMP for regenerating bone in rats. 23,25
A rabbit model used by Bostrom and coworkers consisted
of bilateral, 20-mm long ulnar defects and one of several
treatments of polylactic glycolic acid, autogenous blood, and
four rhBMP-2 doses (27–300 mg) were administered.11 By
8 weeks the X-ray films showed the two higher rhBMP-2
doses promoted union. For histology slides a bone score was
used to compare responses at the wound sites; however, data
reported were difficult to interpret.11 The authors observed
neither polylactic glycolic acid remnants nor multinucleated
giant cells at the recipient sites. This observation is contrary
to reports in other studies where a polylactic polyglycolic
acid delivery system either with or without BMP incited a
multinucleated giant cell reaction.9,19,20,26
jbma
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Figure 6. Representative micrographs for each treatment at 4 and 8
weeks depict the appearance of healing bone at the wound sites. At
4 weeks the 35 mg of rhBMP-2 and collagen treatment produced
numerous trabeculae and by 8 weeks trabeculae consolidated and
cortices developed. (Bone is stained black). The CSD and 0 mg of
rhBMP-2 and collagen treatment did not promote new bone formation. The autograft-treated defects healed by callus formation. von
Kossa stain; original magnification 11.

Figure 5. At week 2, the radiomorphometry data revealed that CSD
and 0 mg of rhBMP-2 and collagen treatments had equivalent radiopacity (indicated by a) but were different than other treatments. Also
at week 2, the radiopacity for the autograft group was greater than
the other cohorts (indicated by b) (p ° 0.05). By 4 and 6 weeks the
CSD group had less radiopacity than contemporary treatments (a),
except for the 0 mg of rhBMP-2 and the collagen group. This relationship among groups was consistent for weeks 6 and 8.

the limited and variable number of replicates per treatment
cohort and lack of statistics, except for a Student’s t test
to analyze the biomechanical data, which indicated no differences among treatments.
Either partially purified BMP or rhBMP-7 has been applied to restore long bone segmental defects in dogs. 5,28,29

Two other important issues concern rhBMP-2 dosing
and wound model selection. We report a 35-mg dose of
rhBMP-2. The elevated rhBMP-2 dose (e.g., 300 mg) selected by the Bostrom group may reflect the need either to
offset liabilities in the delivery system or the instability
caused by a bilateral wound model. We determined in a
pilot study that the unilateral, 20-mm length radius resection was a stable critical-sized defect and did not compromise function for the experimental animal. We also determined bilateral 20-mm ostectomies were neither stable nor
permitted the rabbit to favor one limb and resulted in pseudoarthrosis in many bilateral wounds treated with 35 mg
rhBMP-2. Therefore, in a critical-sized unilateral rabbit
radius model, 35 mg rhBMP-2 promotes bone regeneration
whereas 300 mg rhBMP-2 promotes bone regeneration in
bilateral ulnar defects.
Cook et al. assessed 12 treatment combinations that included seven doses of rhBMP-2 combined with guanidine
extracted, rabbit derived, demineralized matrix to restore
a rabbit ulnar defect model (15 mm in length). 27 Conclusions about treatment outcomes were ambiguous because of

Figure 7. At 4 weeks the upper panel of a defect implanted with 0
mg of rhBMP-2 and collagen (Goldner trichrome stain, original magnification 13.2). Polarized light reveals residual collagen, which can be
seen as swirls of polarized fibers (insert to reader’s right, original
magnification 125). (f ) New bone trabeculae are seen adjacent to
the edge of the defect (insert to reader’s left, original magnification
125).

/
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Figure 8. At 4 and 8 weeks the histomorphometry revealed that the
quantity of bone at CSDs and 0 mg of rhBMP-2 and collagen-treated
groups did not differ but was significantly less than other treatments
(p ° 0.05). The quantity of bone at defects treated with either 35 mg
of rhBMP-2 and collagen or autograft did not differ (indicated by a).

Nilsson et al. used 100 mg of bovine derived, partially
purified BMP delivered by an aggregate of g-carboxyglutamic acid, histone 2-B, and calmodulin to restore 25-mm
long ulnae ostectomies in dogs and reported osseous union
by 12 weeks. 28 Heckman and colleagues prepared 3-mm
long ostectomies in the diaphyses of dogs’ radii. 29 Treatments included combinations of polylactic acid, guanidineinactivated bovine bone matrix, and partially purified BMP
from either bovine or dog sources. The bovine derived
BMP was administered at a dose of 15 mg and the dog
derived partially purified BMP was administered at 1.5 mg
per defect. Results from the Heckman et al. study are difficult to interpret for several reasons: the inequity in sample
sizes of two to six among seven treatment groups; ambiguities in statistical analyses; a xenogeneic (bovine) bone
matrix carrier for allogeneic BMP (which is contradictory
to reports advocating an allogeneic matrix for partially purified BMP 30 – 32 ); and internal fixation on some dogs and
no fixation on others.
Cook et al. reported rhBMP-7 restored 25-mm long,
unilateral, ulnar ostectomies in six adult mongrel dogs. 5
The delivery system was 500 mg of guanidine inactivated
bovine bone matrix. Responses were assessed radiographically and biomechanically. However, the radiographic
‘‘grading’’ was not analyzed statistically and biomechani/
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cal data did not indicate a significant difference between
the two treatments (i.e., 500 mg of bovine carrier and 2.5
mg of rhBMP-7 vs. the unoperated limb).
Recombinant human BMP-2 was used to regenerate
CSDs in dogs’ mandibles and osseous continuity of alveolar clefts in dogs. 12 Toriumi and colleagues observed that
250 mg of rhBMP-2 plus inactivated, bone derived (dog)
matrix restored mandibular continuity by 6 months 33;
Mayer et al. noted 200 mg of rhBMP-2 delivered by
poly(lactide-co-glycolide) regenerated the bony contour of
alveolar clefts in 4 months. 12
A study by Cook and colleagues involved 20-mm length
ostectomies in 28 African green monkeys evenly divided
according to wound sites in either diaphyses of tibiae or
ulnae. 8 Treatments at the 14 ulnar sites included 1 mg
rhBMP-7 delivered in 400 mg of bovine bone matrix, matrix alone, and autogenous grafts. There were five treatments for the 14 tibiae, including four dose combinations
of rhBMP-7. Results from this study were ambiguous because of the experimental design with unequal replicates.
Several groups had only one or two animals per treatment.
Moreover, it was unclear what statistical analyses were
used.
A number of reports detailed rhBMPs for long bone
regeneration in sheep, 34,35 spine fusion in rabbits and
dogs, 9,10,13,36,37 and mandibles in rhesus nonhuman primates. 18 Various doses of BMPs and delivery systems (including polylactic polyglycolic acid, bone derivatives, and
C) were used. Moreover, in a recent clinical report by
Boyne and colleagues, doses of 1.77 to 3.4 mg of rhBMP2 were administered to 12 patients in a collagen delivery
system. 14 The authors claimed this combination was a useful therapy for augmenting the floor of the maxillary sinus.
For our study we chose a commercially available collagen formulation (Helistat威) to deliver rhBMP-2. The
rhBMP-2 dose was derived from previous laboratory work
indicating three doses of rhBMP-2 (17, 35, and 70 mg)
delivered with a porous rod of poly( D,L-lactide) promoted
an equivalent quantity of new bone at 4 and 8 weeks within
20-mm length, unilateral CSDs in rabbits’ radii. 19,20 The
area of new bone measured in this study (Fig. 8) was
consistent with the quantity previously reported. 20 The difference between the two experiments was the carrier for
the rhBMP-2: collagen versus poly( D,L-lactide). It appears
that irrespective of the carrier in a unilateral rabbit radius
model, the same dose of rhBMP-2 (i.e., 35 mg) promotes
nearly identical bone healing. The consistency of these
results helps to fortify the dosing relevancy in bone healing
studies with polymers, such as poly( D,L-lactide) and C.
Moreover, the efficacy of Helistat威 and rhBMP-2 was reported for maxillofacial reconstruction in monkey mandibles and a canine spinal fusion model. 17,18
Helistat威 is manufactured as an absorbable collagen
sponge for hemostasis control. The Helistat威 C is derived
from bovine Achilles tendon treated in a proprietary manner to render the product nonimmunogenic. Although no
adverse sequelae (clinical or histologic) were observed
jbma
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with the Helistat威 C used in our model, there are limited
reports of an immune response to bovine C. 38,39 The immune reaction may be difficult to predict across species and
in varying tissues. Despite the apparent biocompatibility of
the Helistat威 and its capacity as a BMP delivery system,
a laboratory-produced carrier should be developed that is
not derived from animal sources. The laboratory-produced
delivery system may be a useful alternative in situations
where a collagenous delivery system may elicit an immune
response. A laboratory-produced delivery system could be
tailor-made to provide sustained delivery of signaling factors and to degrade in a time-dependent fashion.
The goal of our study was to restore osseous structure
across CSDs in rabbits’ radii with C and a selected dose
of rhBMP-2 and to prove our hypothesis that rhBMP-2
would produce a quantity of bone in the CSD that is equivalent to that promoted by the autograft. We were successful
in fulfilling our goal and proving our hypothesis. Furthermore, the reproducible and clearly defined animal wound
model that is amenable to quantitative morphological assessments confirms this as a test site to validate the efficacy
of segmental bone regenerative therapies. This study and
previous studies exploiting the same wound model underscore the clinical relevance of a well-defined wound model
that can be used to develop a judicious dosing regimen for
the BMPs.

CONCLUSION

Efficacy and biocompatibility was validated for the combination of rhBMP-2 and C. By 8 weeks the combination
was more effective than other treatments in promoting bone
formation at CSDs. The favorable response from rhBMP2 and C suggests that it could be an effective therapy to
regenerate segmental bone defects.
The rhBMP-2 and collagen were generously supplied by the Genetics Institute
(Andover, MA).
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